Literature DB >> 6209556

DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells.

E Flatau, F A Gonzales, L A Michalowsky, P A Jones.   

Abstract

A cell line (T17) was derived from C3H 10T1/2 C18 cells after 17 treatments with increasing concentrations of 5-aza-2'-deoxycytidine. The T17 cell line was very resistant to the cytotoxic effects of 5-aza-2'-deoxycytidine, and the 50% lethal dose for 5-aza-2'-deoxycytidine was ca. 3 microM, which was 30-fold greater than that of the parental C3H 10T1/2 C18 cells. Increased drug resistance was not due to a failure of the T17 cell line to incorporate 5-aza-2'-deoxycytidine into DNA. The cells were also slightly cross-resistant to 5-azacytidine. The percentage of cytosines modified to 5-methylcytosine in T17 cells was 0.7%, a 78% decrease from the level of 3.22% in C3H 10T1/2 C18 cells. The DNA cytosine methylation levels in several clones isolated from the treated lines were on the order of 0.7%, and clones with methylation levels lower than 0.45% were not obtained even after further drug treatments. These highly decreased methylation levels appeared to be unstable, and DNA modification increased as the cells divided in the absence of further drug treatment. The results suggest that it may not be possible to derive mouse cells with vanishingly low levels of 5-methylcytosine and that considerable de novo methylation can occur in cultured lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209556      PMCID: PMC369027          DOI: 10.1128/mcb.4.10.2098-2102.1984

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  19 in total

1.  Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.

Authors:  S M Taylor; P A Jones
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

2.  Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division.

Authors:  C A Reznikoff; D W Brankow; C Heidelberger
Journal:  Cancer Res       Date:  1973-12       Impact factor: 12.701

3.  Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine.

Authors:  J Veselý; A Cihák; F Sorm
Journal:  Cancer Res       Date:  1968-10       Impact factor: 12.701

4.  Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine.

Authors:  J Veselý; A Cihák; F Sorm
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

5.  Biochemical mechanisms of drug resistance. IV. Development of resistance to 5-azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice.

Authors:  J Veselý; A Cihák; F Sorm
Journal:  Int J Cancer       Date:  1967-11-15       Impact factor: 7.396

6.  Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides.

Authors:  P G Constantinides; S M Taylor; P A Jones
Journal:  Dev Biol       Date:  1978-09       Impact factor: 3.582

7.  Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment.

Authors:  P G Constantinides; P A Jones; W Gevers
Journal:  Nature       Date:  1977-05-26       Impact factor: 49.962

8.  Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.

Authors:  R L Momparier; F A Gonzales
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

9.  5-Methylcytosine content of rat hepatoma DNA substituted with bromodeoxyuridine.

Authors:  J Singer; R H Stellwagen; J Roberts-Ems; A D Riggs
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

Review 10.  5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.

Authors:  D D Von Hoff; M Slavik; F M Muggia
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

View more
  28 in total

1.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Polymerase chain reaction-aided genomic sequencing of an X chromosome-linked CpG island: methylation patterns suggest clonal inheritance, CpG site autonomy, and an explanation of activity state stability.

Authors:  G P Pfeifer; S D Steigerwald; R S Hansen; S M Gartler; A D Riggs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Authors:  Jaydeep Bhat; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2015-04-28       Impact factor: 8.110

4.  Demethylation and specific remethylation of the promoter-like region of the L family of mammalian transposable elements.

Authors:  I Nur; E Pascale; A V Furano
Journal:  Cell Biophys       Date:  1989 Aug-Oct

5.  Gene structure and transcription in mouse cells with extensively demethylated DNA.

Authors:  L A Michalowsky; P A Jones
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

6.  Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.

Authors:  L A Michalowsky; P A Jones
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

Review 7.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

8.  Demethylation enhances removal of pyrimidine dimers from the overall genome and from specific DNA sequences in Chinese hamster ovary cells.

Authors:  L Ho; V A Bohr; P C Hanawalt
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

9.  STAT3-mediated effects of methyltransferase inhibitor 5-aza-2'-deoxycytidine on preeclampsia.

Authors:  Xiaoli Zhang; Gang Wang; Hui Li; Xiangming Jiang; Xiaoyong Zhao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

10.  Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.

Authors:  Jonathan C Cheng; Daniel J Weisenberger; Felicidad A Gonzales; Gangning Liang; Guo-Liang Xu; Ye-Guang Hu; Victor E Marquez; Peter A Jones
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.